ArticleAllergy, asthma & immunology research2026
Real-World Efficacy and Safety of Upadacitinib in Korean Patients With Atopic Dermatitis.
Article in Allergy, asthma & immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeUpadacitinib is an oral selective Janus kinase (JAK) 1 inhibitor that has demonstrated high efficacy in clinical trials for patients with atopic dermatitis (AD). However, clinical trial settings may not always reflect real-world practice. This study aimed to assess the real-world efficacy and safety of upadacitinib in AD patients.
methodsOne hundred fifteen AD patients treated with upadacitinib were retrospectively analyzed using medical records. Patients who received treatment for at least 16 weeks were included. In the moderate-to-severe AD group, efficacy was assessed by the proportion of patients achieving Eczema Area and Severity Index (EASI) 50, EASI 75, and EASI 90 at weeks 2 and 16 compared to baseline, whereas efficacy in the mild AD group was evaluated based on the reduction in patient-reported outcomes.
resultsThe mean EASI score significantly decreased after 16 weeks of upadacitinib treatment. At week 2, 67%, 35%, and 6% of moderate-to-severe AD patients achieved EASI 50, EASI 75 and EASI 90, respectively. At week 16, 88%, 71%, and 31% of moderate-to-severe AD patients achieved EASI 50, EASI 75 and EASI 90, respectively. Patient-reported outcome measures improved rapidly within 2 weeks and were sustained through week 16. The most common adverse event was acne, occurring in 35 patients (41.2%) with mild severity. No serious adverse events occurred.
conclusionsUpadacitinib is effective and safe for AD patients in a real-world clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.